References:
- Vannucchi AM, Antonioli E, Guglielmelli P et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythe-mia vera or essential thrombocythemia. Blood 2007; 110: 840–846.
- Vannucchi AM, Antonioli E, Guglielmelli P et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia 2007; 21: 1952–1959.
- Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC. The JAK2V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis—impact on disease phenotype. Eur J Haematol 2007; 79: 508–515.
- Barosi G, Bergamaschi G, Marchetti M et al. JAK2V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007; 110: 4030–4036.
- Tefferi A, Strand JJ, Lasho TL et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007; 21: 2074–2075.
- Vannucchi AM, Antonioli E, Guglielmelli P et al. Clinical correlates of JAK2V617F presence or allele burden in myelopro-liferative neoplasms: a critical reappraisal. Leukemia 2008; 22: 1299–1307.
- Kiladjian JJ, Cassinat B, Turlure P et al. High molecular responserate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006; 108: 2037–2040.
- Samuelsson J, Mutschler M, Birgegard G et al. Limited effects onJAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica 2006; 91: 1281–1282.
- Jones AV, Silver RT, Waghorn K et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 2006; 107: 3339–3341.
- Steimle C, Lehmann U, Temerinac S et al. Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRY-1, and JAK2 V617F. Ann Hematol 2007; 86: 239–244.
- Larsen TS, Bjerrum OW, Pallisgaard N et al. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. Ann Hematol 2008; 87: 847–850.
- Kiladjian JJ, Cassinat B, Chevret S et al. Pegylated Interferon-alfa-2a induces complete hematological and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065–3072.
- Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
- Larsen TS, Christensen JH, Hasselbalch HC et al. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007; 136: 745–751.
- Ishii T, Xu M, Zhao Y et al. Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-alpha 2a in a patient with polycythemia vera. Leukemia 2007; 21: 373–374.
- Hasselbalch HC. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment? Leuk Res 2009; 33: 11–18.